KRAS and neoplasm: In addition to diagnostics, numerous reports now suggest the role of specific KRAS mutation subtypes in prediction of prognosis and therapeutic responses.[15–18] Furthermore, KRAS mutation subtype-specific inhibitor was recently reported as a potential novel therapy.[19] These emerging reports indicate the potential for KRAS mutation subtyping to guide therapeutic decisions in the near future, and signify the importance of identifying all KRAS mutation subtypes present within a tumor.